Overview

Immunosuppressant Regimens for Living Fetuses Study

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Undifferentiated connective tissue diseases (UCTD) are known to increase the risk of pregnancy morbidities, including recurrent pregnancy loss. However, there is no consensus or guideline about the treatment for recurrent pregnancy loss in UCTD patients. Therefore, based on the tendency to thrombosis formation and placental inflammation in the pathogenesis of UCTD, this trial proposes to evaluate the effect of hydroxychloroquine with or without prednisone combined with anticoagulation on pregnancy outcomes in recurrent pregnancy loss patients with UCTD.
Phase:
N/A
Details
Lead Sponsor:
RenJi Hospital
Collaborators:
China-Japan Union Hospital, Jilin University
The First Affiliated Hospital of Anhui Medical University
The First Affiliated Hospital with Nanjing Medical University
Wuxi No. 2 People's Hospital
Xiangya Hospital of Central South University
Treatments:
Aspirin
Calcium heparin
Dalteparin
Enoxaparin
Heparin
Heparin, Low-Molecular-Weight
Hydroxychloroquine
Immunosuppressive Agents
Nadroparin
Prednisone
Tinzaparin